US FDA teams with PatientsLikeMe to access post-market patient data

By Dan Stanton contact

- Last updated on GMT

US FDA will use patient data supplied by PatientsLikeMe to monitor post-market adverse events
US FDA will use patient data supplied by PatientsLikeMe to monitor post-market adverse events

Related tags: Risk

PatientsLikeMe says a deal allowing the US FDA to use its patient-generated data is an “unprecedented step toward enhancing post-market surveillance.”

The collaboration will help the US Food and Drug Administration (FDA) review activities related to risk assessment and risk management in approved drugs post-launch using data provided by the patient group.

Phase IV trials give regulators better insight into the potential adverse events of drugs in a post-market setting, but these studies are only based on a few hundred or thousand patients, PatientsLikeMe President Ben Heywood said.

“We are not running clinical trials,”​ he told this publication. “This collaboration is about post-market surveillance and understanding more about the data that patients are reporting on our open network, and exploring opportunities to learn more about drug safety.”

Furthermore, he continued, PatientsLikeMe is an open network and “the data come from patients who are reporting on their experiences in the real world, and are not influenced by pharma companies or CROs.”

He continued:“Our members are already syncing FitBit data on their PatientsLikeMe profiles and checking in to tell us how they are doing using PatientsLikeMe’s mobile application. However, today, our members use the website - via mobile and browsers - to report side effects and adverse events.”

The deal was announced at the Drug Information Association’s (DIA) annual meeting in Washington today, with the FDA’s willingness to evaluate new data source described by PatientsLikeMe as an “unprecedented step toward enhancing post-market surveillance and informing regulatory science.”

While the FDA is not paying for this data, Heywood said the project could “lead to future FDA-sponsored research projects designed to understand how patient-reported data might be used to enhance post-market surveillance, support regulatory decision making and inform regulatory science.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars